Which of the following statements about antiphospholipid syndrome are correct: (a) diagnosis is based on detection of anti‑neutrophil cytoplasmic antibodies (ANCA) in serum; (b) every patient should receive lifelong low‑molecular‑weight heparin (LMWH); (c) in patients with antiphospholipid syndrome and systemic lupus erythematosus (SLE), low‑dose aspirin and hydroxychloroquine are recommended; (d) women with antiphospholipid syndrome are at risk of developing pre‑eclampsia; (e) coumarin anticoagulants are used for secondary prophylaxis?

Antiphospholipid Syndrome: Statement Analysis

Statements (c), (d), and (e) are correct; statements (a) and (b) are incorrect.

Statement-by-Statement Analysis

a) Diagnosis based on ANCA antibodies - INCORRECT

APS diagnosis is not based on anti-neutrophil cytoplasmic antibodies (ANCA). The diagnosis requires detection of antiphospholipid antibodies, specifically:

• Lupus anticoagulant (LAC)
• Anticardiolipin antibodies (aCL) - IgG or IgM
• Anti-β2 glycoprotein I antibodies (aβ2GPI) - IgG or IgM

These antibodies must be persistently positive on at least two occasions, at least 12 weeks apart 1, 2, 3. ANCA antibodies are associated with vasculitides, not APS—this is a common pitfall in clinical practice.

b) Lifelong LMWH for all APS patients - INCORRECT

Not every individual with APS requires lifelong LMWH. Treatment is stratified based on clinical presentation:

• Thrombotic APS (secondary prophylaxis): Long-term anticoagulation with vitamin K antagonists (warfarin) targeting INR 2-3 is the standard treatment, not LMWH 4, 5, 6
• LMWH is specifically indicated during pregnancy in patients with obstetric or thrombotic APS 1, 7, 1
• Asymptomatic aPL-positive patients without prior thrombosis or pregnancy complications typically receive low-dose aspirin for primary prophylaxis, not anticoagulation 1, 4

The critical distinction: LMWH is pregnancy-specific therapy because warfarin is teratogenic; it is not the standard long-term anticoagulant for non-pregnant APS patients.

c) Low-dose aspirin and hydroxychloroquine in APS with SLE - CORRECT

In patients with APS and SLE, the combination of low-dose aspirin and hydroxychloroquine is strongly recommended 7, 8, 9.

The evidence supporting this recommendation:

• Hydroxychloroquine: Strongly recommended for all SLE patients during pregnancy and preconceptionally 7, 8. It provides immunomodulatory effects, reduces SLE flares, and may decrease APS-related complications 1, 10
• Low-dose aspirin (81-100 mg daily): Recommended for SLE patients at high risk for preeclampsia, which includes those with antiphospholipid antibodies 7, 8
• The 2020 ACR guidelines specifically state: "Women with SLE at risk of pre-eclampsia (especially those with lupus nephritis or positive aPL) should receive LDA" 8

This combination addresses both the autoimmune disease activity and thrombotic risk inherent in APS-SLE overlap.

d) Women with APS at risk for preeclampsia - CORRECT

Women with APS are definitively at increased risk of developing preeclampsia 1, 11.

The evidence is compelling:

• The 2020 ACR guidelines explicitly state: "presence of aPL regardless of clinical history is considered a risk factor for development of preeclampsia" 1
• Patients with lupus nephritis and antiphospholipid antibodies "are more at risk of developing pre-eclampsia and should be monitored more closely" 5
• Meta-analyses have found associations between preeclampsia and lupus anticoagulant, anticardiolipin, and anti-β2 glycoprotein I antibodies 11
• The FDA drug label for hydroxychloroquine notes that pregnant women with SLE are "at increased risk of adverse pregnancy outcomes, including...preeclampsia" 12

Clinical implication: Prophylactic low-dose aspirin (81-100 mg daily) should be initiated before 16 weeks gestation in aPL-positive pregnant women as preeclampsia prophylaxis 1.

e) Coumarin anticoagulants for secondary prophylaxis - CORRECT

Vitamin K antagonists (coumarins like warfarin) are the standard treatment for secondary prophylaxis after thrombotic events in APS 4, 5, 6.

The guideline recommendations are clear:

• "In non-pregnant patients with SLE and APS-associated thrombosis, long-term anticoagulation with oral anticoagulants is effective for secondary prevention of thrombosis" 5
• The 2024 AHA/ASA stroke prevention guidelines recommend "vitamin K antagonist (VKA) therapy with a target international normalized ratio of 2 to 3" for patients with APS and prior unprovoked venous thrombosis 4
• Target INR is typically 2-3, though some high-risk patients (particularly those with arterial thrombosis or triple-positive antibodies) may require higher intensity anticoagulation 6

Important caveat: Direct oral anticoagulants (DOACs) are generally not recommended for high-risk APS patients, particularly those who are triple-positive or have arterial thrombosis, as they have shown inferior efficacy compared to warfarin 4, 6.

Key Clinical Pitfalls to Avoid

1. Do not confuse ANCA with antiphospholipid antibodies - completely different disease entities
2. Do not use LMWH as lifelong therapy - it's pregnancy-specific; use warfarin for long-term anticoagulation outside pregnancy
3. Do not withhold hydroxychloroquine in pregnant SLE/APS patients - it's safe and beneficial 7, 12, 10
4. Do not use DOACs in high-risk APS - warfarin remains superior 4, 6
5. Do not forget aspirin prophylaxis for preeclampsia prevention in aPL-positive pregnancies 1